[ TRANSACTION RECORD ]

Goldman Sachs Asset Management Investment in Pfizer Seagen Platform — 2023

VERIFIED VECTOR ID: 002218 · tx-314
M SOURCE NODE — FUNDER
Finance United States
$43,000,000,000
EQUITY
14/12/2023
Q DESTINATION NODE — RECIPIENT
SPV United States
Amount (USD)
$43.0B
Flow Type
EQUITY
Transaction Date
14/12/2023
Primary Source
Funder Profile [ M ]
AUM 2800000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity Type SPV
Jurisdiction United States
Intelligence Note

Pfizer Inc. finalized the 43 billion dollar acquisition of Seagen to establish a world-class oncology organization focused on advancing targeted antibody-drug conjugates for cancer care. This transaction is one of the largest in biotech history, expanding Pfizer’s therapeutic capabilities. This deal represents a massive deployment of institutional capital into the advancement of oncology medicine.